Her-2/Neu Intracellular Domain Protein
Male Breast Cancer
University of WashingtonvaccinePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 89/ 100
Competitive context
10 Active assets in the Male Breast Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Wake Forest University Health Sciences | Phase 2 | BBB |
FILGRASTIM University of Washington | Phase 2 | BBB |
Irinotecan University of California, Irvine | Phase 2 | BBB |
Inno-206 National Cancer Institute (NCI) | Phase 2 | BBB |
Cediranib University of Chicago | Phase 2 | BB |
View all 50 →
Same molecule, other indications
Her-2/Neu Intracellular Domain Protein is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →